RNAi Therapeutics 2008 : Market Research Report

RNAi Therapeutics 2008

Published by: Select Biosciences Limited

Published: Nov. 1, 2007 - 171 Pages

Chapter I. Executive Summary
Chapter II. Opportunities and Challenges In the Space
Chapter III. RNAi Therapeutics Market Analysis: Results of Market Survey performed by Select Biosciences to Analyze the Market Landscape: Geographic Distribution of the Respondent Pool; Affiliation of the Respondent Pool; Challenges Impacting RNAi Therapeutics by Therapeutic/Disease Area; Top-Most Challenge by Therapeutic/Disease Area; Timeline of Impact by Therapeutic Area; Delivery Approach by Therapeutic Area; Drug Target Classes amenable to RNAi Therapeutics; Druggability Factors; Factors that determine whether a given drug target will be druggable via RNAi-based therapeutics; Key Challenges for RNAi-based therapeutics; Opportunities in the RNAi-based Therapeutics marketplace -- [ie., what products/services would be of value to the industry]
Chapter IV. RNAi Therapeutics in Development: Cancer; Cardiac Disease; Immunologic Disease; Infectious Disease; Inflammation; Lifestyle; Metabolic Disease; Neurologic Disease; Opthalmic Disease; Renal Disease; Respiratory Disease
Appendix I. Research Methodology
Appendix II. Technology Trends in the RNA Interference (RNAi) Space: Scope; End-user Segmentation; Technologies for Inducing RNAi; Methods for Detecting Gene Silencing; Libraries of siRNAs/shRNAs to Knock-down Genes en masse; Publicly-Available Large-scale Mammalian RNAi Libraries; The RNAi Consortium (TRC): A Cooperative Effort to; Generate Large Libraries for Gene Knockdown; Comparison of Strategies for Target Validation, Especially in the Pharmaceutical Industry; Market Shifts in the RNAi Space: Where is the Field Heading?; MicroRNA-based RNAi Interference: The Leading-Edge of the RNAi Space; Biological Function of microRNAs; Role of MicroRNAs in Cancer; MicroRNAs in Human Cancer: The Different Molecular Entities Identified and the Conflicting Experimental Evidence Thus Far; SWOT Analysis of the Various Technologies in the RNAi Space, and Vendors Commercializing These Technologies
Appendix III. Intellectual Property [IP] in the RNAi Therapeutics Space: Timeline; Key Founding IP; RNAi Patent Landscape and key claims in major patents; RNAi Therapeutics IP Landscape—2D Maps of the Space, annotated with patent filings for some of the key companies in the RNAi therapeutics space
Appendix IV. Relevant Company Profiles: Alnylam Pharmaceuticals, Inc.; Benitec Ltd.; Calando Pharma; Intradigm; Nastech Pharmaceutical Company, Inc.; Nucleonics, Inc.; Opko Corporation; Quark Biotech; RXi Pharmaceuticals; Santaris Pharma A/S; Silence Therapeutics AG

Abstract

This is the latest RNAi-based Therapeutics Market Report from Select Biosciences. This report presents an up-to-date thorough analysis of the RNAi therapeutics landscape based upon our continuing coverage of this dynamic marketplace. This report presents an exhaustive analysis of all the therapeutics areas where research efforts using RNAi-based therapeutics are being focused: From Research/Pre-Clinical through Phase III Clinical Trials. Select Biosciences proprietary market survey addresses druggability trends, drug target classes (where RNAi therapeutics will impact) and different therapeutic areas in terms of challenges/opportunities/quantitative industry metrics—this highly valuable dataset is based on an extensive market analysis.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

RNAi Therapeutics 2008

Table of Contents

Abstract